For many postmenopausal women with early-stage breast cancer, treatment includes an aromatase inhibitor. Current guidelines recommend that women stay on an aromatase inhibitor for five years. But might staying on treatment for 10 years confer additional benefit? A recent study suggests the answer is yes, for some women.
Sue Rochman 